Current Knowledge of Targeted-release Budesonide in Immunoglobulin A Nephropathy: A Comprehensive Review

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Jan 23

PMID 36685528

Authors

Jian Liao

Yijing Zhou

Xiuqin Xu

Ke Huang

Pengtao Chen

Yuhao Wu

Biao Jin

Qianlong Hu

Guanlin Chen

Shankun Zhao

Affiliations

Soon will be listed here.

Abstract

Immunoglobulin A (IgA) nephropathy is a common autoimmune kidney disease. Accumulating studies showed that IgA nephropathy may be partially correlated with mucosal immune system dysfunction. Systemic corticosteroid treatment exerts an essential protective effect against renal deterioration in IgA nephropathy. However, long-term use of corticosteroids may cause systemic side effects. The novel targeted-release formulation (TRF) of budesonide has been shown to deliver the drug to the distal ileum with the aim of minimizing adverse events for patients with IgA nephropathy. In this review, we have summarized all the current evidence of the effects of TRF-budesonide protecting against IgA nephropathy. Three randomized controlled trials (RCTs), one cohort, two case reports, and an ongoing Phase 3 trial (Part B, NCT03643965), were under comprehensive review. These included studies demonstrated that TRF-budesonide could remarkably reduce proteinuria, hematuria, and creatinine, as well as preserve renal function. The local immunosuppressive effects exhibited by TRF-budesonide may represent a novel and promising approach to treating IgA nephropathy. However, the current evidence was only derived from limited trials. Therefore, more well-designed RCTs are still warranted to validate the curable profile of TRF-budesonide in treating IgA nephropathy.

Citing Articles

Targeted-release budesonide: A comprehensive review on its potential in IgA nephropathy.

Qi F, Zeng H, Zhang J Heliyon. 2025; 11(4):e42729.

PMID: 40061933 PMC: 11889547. DOI: 10.1016/j.heliyon.2025.e42729.

Factors influencing early response of IgA nephropathy following targeted-release budesonide (TRB) treatment: preliminary results from a multicenter study.

Keskinis C, Moysidou E, Kapsia E, Vaios V, Bintas C, Trivyza M Clin Kidney J. 2025; 18(1):sfae364.

PMID: 39967795 PMC: 11833314. DOI: 10.1093/ckj/sfae364.

The evolving understanding of systemic mechanisms in organ-specific IgA nephropathy: a focus on gut-kidney crosstalk.

Wang X, Zhou X, Qiao X, Falchi M, Liu J, Zhang H Theranostics. 2025; 15(2):656-681.

PMID: 39744688 PMC: 11671385. DOI: 10.7150/thno.104631.

Experimental measurement, thermodynamic analysis, and mathematical modeling for budesonide solubility in 1-propanol + water mixtures at T = (293.2 to 313.2) K.

Mohammadian E, Dashti M, Martinez F, Jouyban A BMC Chem. 2024; 18(1):190.

PMID: 39342251 PMC: 11439214. DOI: 10.1186/s13065-024-01297-x.

Therapy of IgA nephropathy: time for a paradigm change.

Barratt J, Lafayette R, Floege J Front Med (Lausanne). 2024; 11:1461879.

PMID: 39211339 PMC: 11358106. DOI: 10.3389/fmed.2024.1461879.

References

Yata N, Nakanishi K, Shima Y, Togawa H, Obana M, Sako M . Improved renal survival in Japanese children with IgA nephropathy. Pediatr Nephrol. 2008; 23(6):905-12. PMC: 2335295. DOI: 10.1007/s00467-007-0726-5. View

Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M . Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014; 46(11):1187-96. PMC: 4213311. DOI: 10.1038/ng.3118. View

Cheng J, Zhang X, Tian J, Li Q, Chen J . Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis. Int J Clin Pract. 2012; 66(10):917-23. DOI: 10.1111/j.1742-1241.2012.02970.x. View

Rauen T, Floege J . Inflammation in IgA nephropathy. Pediatr Nephrol. 2017; 32(12):2215-2224. DOI: 10.1007/s00467-017-3628-1. View

Qian G, Zhang X, Xu W, Zou H, Li Y . Efficacy and safety of glucocorticoids for patients with IgA nephropathy: a meta-analysis. Int Urol Nephrol. 2019; 51(5):859-868. DOI: 10.1007/s11255-019-02094-5. View

Zaza G, Bernich P, Lupo A . Incidence of primary glomerulonephritis in a large North-Eastern Italian area: a 13-year renal biopsy study. Nephrol Dial Transplant. 2012; 28(2):367-72. DOI: 10.1093/ndt/gfs437. View

Selvaskandan H, Barratt J, Cheung C . Immunological drivers of IgA nephropathy: Exploring the mucosa-kidney link. Int J Immunogenet. 2021; 49(1):8-21. DOI: 10.1111/iji.12561. View

Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B . Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med. 2015; 373(23):2225-36. DOI: 10.1056/NEJMoa1415463. View

Mestecky J, Novak J, Moldoveanu Z, Raska M . IgA nephropathy enigma. Clin Immunol. 2016; 172:72-77. PMC: 5159197. DOI: 10.1016/j.clim.2016.07.011. View

10.

Boyd J, Cheung C, Molyneux K, Feehally J, Barratt J . An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int. 2012; 81(9):833-43. DOI: 10.1038/ki.2011.501. View

11.

De Angelis M, Montemurno E, Piccolo M, Vannini L, Lauriero G, Maranzano V . Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). PLoS One. 2014; 9(6):e99006. PMC: 4055632. DOI: 10.1371/journal.pone.0099006. View

12.

Fellstrom B, Barratt J, Cook H, Coppo R, Feehally J, De Fijter J . Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017; 389(10084):2117-2127. DOI: 10.1016/S0140-6736(17)30550-0. View

13.

Thompson A, Carroll K, Inker L, Floege J, Perkovic V, Boyer-Suavet S . Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. Clin J Am Soc Nephrol. 2019; 14(3):469-481. PMC: 6419287. DOI: 10.2215/CJN.08600718. View

14.

Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J . Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2022; 103(2):391-402. DOI: 10.1016/j.kint.2022.09.017. View

15.

Bos A, Aleyd E, van der Steen L, Winter P, Heemskerk N, Pouw S . Anti-FcαRI Monoclonal Antibodies Resolve IgA Autoantibody-Mediated Disease. Front Immunol. 2022; 13:732977. PMC: 8965572. DOI: 10.3389/fimmu.2022.732977. View

16.

Reich H, Troyanov S, Scholey J, Cattran D . Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007; 18(12):3177-83. DOI: 10.1681/ASN.2007050526. View

17.

Coppo R . The intestine-renal connection in IgA nephropathy. Nephrol Dial Transplant. 2014; 30(3):360-6. DOI: 10.1093/ndt/gfu343. View

18.

Berger J, HINGLAIS N . [Intercapillary deposits of IgA-IgG]. J Urol Nephrol (Paris). 1968; 74(9):694-5. View

19.

Lingaraj U, Aralapuram K, Chikkanayakanhalli S, Vishwanathan A, Vankalakunti M . Successful treatment of a patient with posttransplant IgA nephropathy with targeted release formulation of budesonide. Saudi J Kidney Dis Transpl. 2020; 31(2):521-523. DOI: 10.4103/1319-2442.284029. View

20.

Natale P, Palmer S, Ruospo M, Saglimbene V, Craig J, Vecchio M . Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev. 2020; 3:CD003965. PMC: 7066485. DOI: 10.1002/14651858.CD003965.pub3. View